Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acetyl-CoA carboxylase 1 (ACC1) is a cytosolic enzyme that catalyzes the carboxylation of acetyl-CoA to malonyl-CoA. This reaction is the first and rate-limiting step in de novo fatty acid biosynthesis. ACC1 is a biotin-dependent enzyme and plays a central role in lipid metabolism by providing malonyl-CoA, which serves as both a substrate for fatty acid synthesis and an inhibitor of fatty acid oxidation. Altered expression or activity of ACC1 has been implicated in metabolic diseases such as obesity and diabetes, and overexpression can contribute to tumorigenesis making it an attractive target for cancer therapy research.
Inhibition of ACC1 leads to decreased malonyl-CoA levels, reducing fatty acid synthesis and increasing fatty acid oxidation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acetyl-CoA Carboxylase 1 (ACC1).